profit from every $100 of sales.
$0$100
Takeda Pharmaceutical
$20.84-0.43% today
+48.8% in 1 year
1-year low $14.011-year high $21.19
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $98.54 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Takeda Pharmaceutical sold, what it kept, and what it did with the cash.
Sales went from ¥3.57 trillion in 2022 to ¥4.58 trillion in 2025, with ¥108 billion of profit last year.
SalesProfit
Takeda Pharmaceutical handed back 52% of the cash it generated last year.
¥302.5B
Free cash flow 2025¥677.6B
Bought back its own shares¥51.9B
Paid as dividends¥302.5B
Cash vs. debt¥385.1B vs. ¥4.52T
Takeda Pharmaceutical vs. similar companies
Takeda Pharmaceutical grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Takeda Pharmaceutical | 98.5× · Very expensive | ||
 Merck KGaA | 25.9× · Fair price | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive | ||
 Sun Pharmaceutical Industries | 39.8× · Expensive |
Compare Takeda Pharmaceutical with Eli Lilly
AI analysis
An AI analyst reads Takeda Pharmaceutical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of JPY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,569,006 | 4,027,478 | 4,263,762 | 4,581,551 | |
| 2,462,160 | 2,783,406 | 2,837,084 | 3,001,334 | |
| 546,043 | 587,812 | 366,165 | 486,061 | |
| 1,008,154 | 1,156,463 | 900,328 | 1,073,791 | |
| 230,059 | 317,017 | 144,067 | 107,928 | |
| 72.94 | 100.97 | 45.58 | 33.62 | |
| 69.0% | 69.1% | 66.5% | 65.5% | |
| 15.3% | 14.6% | 8.6% | 10.6% | |
| 6.4% | 7.9% | 3.4% | 2.4% |
Balance sheet
| In millions of JPY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 13,178,018 | 13,957,750 | 15,108,792 | 14,248,344 |
| Cash | 849,695 | 533,530 | 457,800 | 385,113 |
| Total debt | 4,345,411 | 4,382,341 | 4,843,752 | 4,515,265 |
| Total liabilities | 7,494,495 | 7,603,079 | 7,834,787 | 7,312,365 |
| 5,683,019 | 6,354,122 | 7,273,264 | 6,935,084 | |
| 3,154 | 3,140 | 3,161 | 3,211 | |
| 3.3% | 3.6% | 1.1% | 2.2% | |
| 4.0% | 5.0% | 2.0% | 1.6% |
Cash flow
| In millions of JPY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,123,105 | 977,156 | 716,344 | 1,057,182 | |
| 186,037 | 633,689 | 480,730 | 379,625 | |
| 937,068 | 343,467 | 235,614 | 677,557 | |
| Dividends paid | 283,665 | 279,416 | 287,188 | 302,498 |
| 77,531 | 26,929 | 2,326 | 51,860 | |
| 43,374 | 60,672 | 70,871 | 72,867 |
Valuation
- 98.5×
- 0.3×
- –
- 1.4×
- 2.3×
- 15.7×
- 13.8×
- 6.4%
- 1.0%
- 2.8%
Profitability
- 65.5%
- 10.6%
- 2.4%
- 31.4%
- 0.0%
- 1.8%
- 2.6%
- 1.2%
- 3.6%
- 15.0%
Growth
- +8.7%
- −22.8%
- −5.6%
- −6.8%
- +0.1%
Financial health
- 5.9×
- 0.66
- 31.6%
- 0.0×
- 1.09
- 0.70
- 0.29
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 958
Top 46%of 888
Bottom 9%of 600
Bottom 43%of 889
Top 16%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | 0.28 | 0.21 | +33.3% |
| Jan 29, 2026 | 0.48 | 0.55 | −12.7% |
| Oct 30, 2025 | 0.44 | 0.44 | +0.0% |
| Jul 30, 2025 | 0.52 | 0.47 | +10.6% |
| Jun 25, 2025 | -0.22 | – | – |
| Jan 30, 2025 | 0.42 | 0.63 | −33.3% |
| Oct 31, 2024 | 0.44 | 0.39 | +12.8% |
| Jul 31, 2024 | 0.56 | 0.37 | +51.4% |
2.8%of the share price, paid each year
On $1,000 invested$28a year at today's yield, before tax
−6.8%2020 to 2025
Raised–not every year
Paid per share, each year
$0.73 in 2015 → $0.60 in 2025
How safe it looks
280.3% of its profit
Room to growStretchedMore than it earns: 44.6%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
32No pass
Philip Fisher
24No pass
Peter Lynch
25No pass
Joel Greenblatt
1No pass
Charlie Munger
17No pass
Terry Smith
12No pass
Questions about Takeda Pharmaceutical
Is Takeda Pharmaceutical a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Takeda Pharmaceutical AI analysis
What does Takeda Pharmaceutical do?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It is in Drug Manufacturers - Specialty & Generic, based in Tokyo, Japan.
Does Takeda Pharmaceutical pay a dividend?
Yes. At today's price the dividend is 2.8% a year, about 280% of its yearly profit. In 2025 it paid out $302 billion in dividends.
Is Takeda Pharmaceutical stock halal?
No. Takeda Pharmaceutical does not pass our halal screen: its debt is 43% of its market value, at or above the 33% limit. How we check
How has Takeda Pharmaceutical stock done over the past year?
Up 48.8% over the past twelve months, to $20.84. It traded between $14.01 and $21.19, close to its high.
Who are Takeda Pharmaceutical's competitors?
The largest listed companies in the same industry are Merck KGaA, Galderma Group, Teva Pharmaceutical Industries and Sun Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Takeda Pharmaceutical's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.